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Case presentation
A 33-year-old man was first admitted to the Nephrology Department
of HOpital Tenon for recurrent cystine stone formation. At age 20 he
suffered the first episode of renal colic and at age 25 passed a stone for
the first time; stone analysis revealed cystine. A bladder stone re-
mained, however, and was removed by surgery one year later. At that
time moderate atrophy of the right kidney was noted on intravenous
pyelograms. He was advised to maintain a standard regimen to ensure
abundant alkaline diuresis, but between 25 and 30 years of age, he
passed numerous stones and required surgery to remove a stone from
the left ureter; yet another stone remained in the left kidney.
Physical examination and renal function were normal. The urine was
strongly positive by Brand's reaction. Because stone formation was
bilateral and poorly controlled by alkaline diuresis, treatment with
D-penicillamine was initiated. The urine remained protein free for 3
months, but after 3 months of treatment, proteinuria was detected at a
level of 3 g/24 hours. Administration of D-penicillamine was discontin-
ued. A right renal biopsy revealed modest thickening of the glomerular
capillary walls and rare, silver-staining epimembranous deposits. Typ-
ical epimembranous deposits of IgG were detected by immunofluores-
cence analysis. Rare C3 deposits also were observed.
Discontinuation of D-penicillamine was associated with a decrease of
proteinuria, and urinalysis was normal after 3 months. Within the next
12 months, the patient excreted numerous stones, and a large coralli-
form stone was detected in the left kidney. Aggressive alkaline diuresis
was reinitiated and the size of the stones decreased. Alkaline diuresis
could not be maintained at a sufficient level, however, and new stones
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again were formed in both kidneys. There was no proteinuria. Because
stone disease was severe and bilateral and could not be controlled by
alkaline diuresis, another course of treatment with D-penicillamine was
initiated. Prior to therapy, however, a second renal biopsy was per-
formed to ascertain the degree of healing of the previous glomerular
lesion. Renal parenchyma was normal and immunofluorescent exami-
nation was negative. Three months after initiation of the second course
of therapy, proteinuria again was detected at a level of 0.8 g/24 hours.
Again, D-penicillamine was discontinued promptly, and the proteinuria
regressed within 3 months. The patient was advised to maintain an
alkaline diuresis. He relocated shortly thereafter and was lost to
followup.
Discussion
DR. PIERRE VERROUST (Directeur de Recherche, INSERM,
Hopital Tenon, Paris, France): The patient under discussion
today presented with the typical clinical and pathologic symp-
toms of nephritis induced by D-penicillamine [1—81. This ad-
verse drug effect was first described in patients with rheumatoid
arthritis; data published over the past 20 years were recently
reviewed by Fillastre, Druet and Mery [I]. The incidence of
renal involvement among those treated with D-penicillamine
varies from 7% to 20%, but the severity of the disorder does not
appear to be related to the dosage used. Proteinuria rarely
occurs within the first 3 months of treatment but, when present,
eventually leads to nephrotic syndrome in 50% of the protein-
uric patients. The histologic pattern in 115 of 135 patients
analyzed was typical of membranous glomerulonephritis
(MGN) [1]. The lesions are frequently detectable only by
indirect immunofluorescence analysis because argyrophylic
"spikes" are visible in only 50% of the biopsy specimens and
even then are often present in small numbers. The outcome of
the glomerulonephritis (GN) is generally favorable and never
results in renal failure. Proteinuria usually decreases after
withdrawal of D-penicillamine, disappearing completely within
6 to 18 months. The experience of patients who receive a
second course of treatment after recovery from nephritis varies;
some develop proteinuria again, whereas others do not.
The clinicopathologic picture just described applies to the
majority of cases, but an occasional patient does develop more
severe renal disease. Six patients have developed a lupus-like
syndrome [reviewed in Ref. 1]. Three of these studied histolog-
ically had typical features of MGN, focal necrotic GN, or a
diffuse proliferative GN. Nine patients presented with severe
and rapidly progressive crescentic GN and clinical features of
Goodpasture's syndrome [9—IS]. Immunoglobulin deposits
were linear in one patient and granular in the others. Of these 9
patients, the first 5 died, whereas the 4 more recently reported,
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sive agents, and plasmapheresis, survived with various degrees
of renal failure; one required hemodialysis.
The patient under discussion appears to be quite typical of
those with classic MON induced by D-penicillamine. His phy-
sicians had to balance the small chance of his developing severe
renal disease after D-penicillamine treatment against the virtual
certainty of continuous stone formation.
The experience with this patient offers us an opportunity to
address several questions about the pathogenesis of immune
deposits in penicillamine-induced renal disease and, by extrap-
olation, in other forms of MGN: How are these immune
deposits formed? What regulates their development? Why did
they develop in this patient and not in all patients receiving the
drug? What accounts for their rapid regression?
In-situ formation of immune deposits
in tnembranous nephritis
Currently available data suggest that the glomerular deposits
were most likely formed by binding of free circulating antibod-
ies to an antigen already present in the patient's glomerulus.
Evidence for this hypothetical mechanism in MON comes
largely from studies of models initially thought to exemplify the
deposition of circulating immune complexes [16, 17].
In 1959, Heymann et al described a model of MON induced
by immunizing rats with material obtained from the brush
border of the proximal convoluted tubule [18, 19]. Within a few
weeks, the animals develop glomerular lesions bearing close
similarity to MON in humans, and heavy proteinuria, which
leads to the nephrotic syndrome. In 1968 Edgington and co-
workers suggested that the immune deposits resulted from
glomerular trapping of circulating immune complexes contain-
ing antigens derived from the brush border. In addition, these
workers isolated a nephritogenic fraction from the brush bor-
der, which they called RTEa5 [20]. Subsequent experiments
revealed, however, that Heymann nephritis could be induced
"passively" by injecting rats with heterologous anti-brush-
border antibodies [2 1—231 and even ex vivo in isolated perfused
kidney systems devoid of circulating antigen [24, 25]. These
studies led to the conclusion that the nephritogenic antigen was
expressed in the glomerulus. Key experiments reported in 1982
by Neale and colleagues showed that immunoglobulins eluted
from glomeruli of rats with active Heymann nephritis could
bind in vitro to glomerular sections and could induce glomerular
immune deposits when perfused in an isolated kidney system
[26, 27]. These observations taken together with the subsequent
identification of the 330 kDa nephritogenic antigen [28—33]
demonstrate that the immune deposits in the glomerulus were
formed in situ. Data obtained in other models of MON suggest
that this mechanism might be more general. The MON of
chronic serum sickness was long considered to be related to
deposition of small, circulating immune complexes [34], but
recent studies indicate that the initial event might be the binding
of cationic bovine serum albumin (BSA) to the anionic charges
of the glomerular capillary wall [35, 36]. Anti-BSA antibodies
formed subsequently bind to this foreign antigen already local-
ized within the glomerular capillary wall. A similar process may
occur in lupus nephritis, as suggested by the observation that
DNA can bind to the glomerular capillary wall [37, 38]. These
observations indicate that immune deposits can be formed in
situ in at least 3 models long thought to be mediated by
deposition of circulating immune complexes.
The most striking aspects of MON induced by D-penicilla-
mine are, of course, the transient character of this lesion and its
ability to resolve after the drug is withdrawn, and in some
cases, even if treatment is continued [1, 5, 6]. These features
are distinct from those observed in most cases of human MON
or in the experimental "in-situ" models of MON that I have
mentioned; in these circumstances, the deposits persist for
prolonged periods.
During this discussion I would like to review some of the
recent data suggesting that in-situ formation of immune com-
plexes can be responsible both for persistent as well as for
transient deposition of immune reactants. This extreme varia-
tion in outcome might be explained by the properties of the
antigen involved, by the immune response type, or by both.
Regulation of immune response and genetic makeup
Experimental studies using chronic administration of mercu-
ric chloride (HgCl,) have provided valuable information for our
understanding of drug-induced glomerulonephritis. These stud-
ies have suggested that a nephritogenic response might be
genetically controlled and that the autoimmune process could
be autoregulated [39—52].
Autoimmune nephritis in Brown-Norway (BN) rats. Brown-
Norway rats receiving 0.1 mg/lOO g body weight 3 times weekly
of HgCl2 develop a biphasic type of glomerulonephritis charac-
terized by heavy proteinuria and nephrotic syndrome [39—41].
The first phase, characterized by the presence of linear deposits
of antibodies along the glomerular basement membrane in a
typical, smooth linear pattern, is referred to as the anti-OBM
phase. After 2 to 3 weeks, a second phase develops, character-
ized by the appearance of granular deposits typical of MON. At
this time, immune complexes (of unknown composition) are
detectable in the circulation, but whether they participate in
glomerular immunoglobulin deposition is unknown; conse-
quently, binding of antibodies to an intrinsic component of the
glomerular capillary wall cannot be excluded. Mercuric-chlo-
ride-induced glomerulonephritis is associated with a number of
other autoimmune manifestations [42—44], including spleen and
lymph-node enlargement due to lymphoproliferation of B- and
T-helper cells, increased serum immunoglobulin (particularly
IgE) levels, and the presence of several autoantibodies in
plasma.
The pathogenesis of this experimental disease has been the
object of intense investigation, both in vitro and in vivo.
Administration of HgCI2 appears to cause an abnormal T-helper
cell cooperation that requires the presence of Ia-positive cells.
The most likely explanation is that HgCI2 induces autoreactive
T-helper cells (probably anti-Ia), which then stimulate La-
bearing B-cells [45]. Most of the autoimmune abnormalities that
derive from this type of polyclonal activation disappear spon-
taneously, and rats that survive the initial phase of the disease
heal completely. The mechanisms involved in this autoregula-
tion process include the delayed emergence of suppressor
T-cells [46, 47]. Their specificity is poorly defined, but there is
evidence that antiidiotypic T-cells are involved.
Effects of HgCI2 in Lewis rats. Whereas BN rats regularly
develop biphasic renal disease in response to HgCI2 adminis-
tration, Lewis rats are totally resistant. This resistance is not
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explained by the absence of the relevant auto-antigens but is
associated with the early development of suppressor T-cells.
Indeed, recent studies show that HgCI2 induces an increase in
suppressor/cytotoxic T-cells in the spleen and lymph nodes and
that this increase starts at day 7 and peaks at day 15 [481. All
T-cell functions tested were depressed. Furthermore, pretreat-
ment with HgCI2 down-modulates other autoimmune diseases,
such as experimental autoimmune encephalitis and Heymann
nephritis [49]. In the latter case, the response to gp330 is
decreased, and consequently the development of glomerular
immune deposits is considerably blunted and proteinuria does
not develop.
Genetic control of HgC12-induced autoimmune glomerulone-
phritis. The genetic control of the susceptibility to HgCI,-
induced autoimmune disease has been studied in detail [50—52].
Using segregants obtained from BN and Lewis rats, it has been
shown that susceptibility is inherited as an autosomal trait and
involves approximately 3 genes, including one linked to the
major histocompatibility complex, localized within the RTI-B
region (the equivalent of the DR region in humans). Studies of
other strains have proved particularly interesting because they
show that MGN can occur in the absence of the initial phase of
anti-GBM nephritis.
Mercuric chloride-induced autoimmune glomerulonephritis is
of interest for several reasons: (1) Several species are suscep-
tible to the experimental disease [53, 54]; (2) Although data are
limited, D-penicillamine-induced GN in rats [55—57] exhibits a
strain specificity similar to that observed with HgCl2-induced
GN. These latter studies with D-penicillamine have not been as
extensive, and at present only linear and granular immunoglob-
ulin deposits have been reported; (3) A genetic predisposition
[58—60] to D-penicillamine-induced nephropathy also exists in
humans; individuals who are positive for DR3 are more likely
than others to develop it [61]. Although rarely, D-penicillamine-
induced nephropathy has been associated with linear glomeru-
lar immunoglobulin deposits. It can also be associated with
other autoimmune manifestations.
The role of antigenic properties
The antigen responsible for Heymann nephritis: gp330. The
pathogenic antigen gp330, a 330 kDa glycoprotein expressed by
glomerular epithelial cells, was identified by Kerjaschki and
Farquhar using lentil-lectin-affinity chromatography and gel
filtration of proximal tubule brush border solubilized by sodium
deoxycholate [28, 29]. We used a different approach based on
raising monoclonal antibodies against the brush border and
selecting those that also reacted against the glomerulus [30—33].
The screening test that we used, that is, indirect immunofluo-
rescence performed on kidney sections incubated with the
hybrid supernatants, allowed us to identify 7 monoclonal anti-
bodies displaying reactivity with renal tissue similar to that
observed with anti-gp330 antibodies [33]: the brush border of
the proximal convoluted tubule is stained intensely, whereas
the glomerulus exhibits a very fine, dispersed, and punctuated
fluorescence [29, 621. Comparative immunoprecipitation of
1251-radiolabeled brush-border proteins with monoclonal anti-
bodies and with polyclonal antibodies raised against the antigen
prepared according to Kerjaschki et al [28] showed that the two
proteins have the same apparent molecular weight. They also
share the same characteristic ultrastructural localization [29,
62] and thus they are most likely identical.
One of the most puzzling aspects of gp330 is its concentration
within cell surface structures known as "coated pits." These
structures, characterized by a thick clathrin (a highly conserved
180 kDa protein which, together with a smaller peptide, forms
polyhedral structures) coat on the cytoplasmic aspect of the cell
membrane, play a critical role in receptor-mediated endocy-
tosis. This process occurs in virtually all cell types and involves
the binding of ligands to membrane receptors that become
concentrated in the coated pits. During endocytosis, the latter
give rise to coated vesicles, which rapidly lose their clathrin
coat to form smooth cytoplasmic endosomes. Proton pumps
acidify the interior of endocytic vesicles, thus allowing disso-
ciation of the ligand/receptor complex. The fate of the individ-
ual components is variable; some receptors are destroyed,
whereas others are recycled.
The luminal aspect of the proximal convoluted tubule is
characterized by a well-developed brush border that can be
subdivided in two microdomains [63, 64]: the microvilli cen-
tered by a bundle of actin filaments, and the intermicrovillar
domain, characterized by a thick clathrin coating. Whereas
most proteins are evenly distributed on the luminal membrane,
some are selectively distributed: maltase, a 300 kDa protein, is
excluded from the intermicrovillar domain, whereas gp330 is
selectively concentrated on the luminal aspect of the intermi-
crovillar areas, as well as within thick-walled vesicles immedi-
ately beneath the brush border.
On glomerular cells, gp330 is detectable in coated pits,
including those localized on the insertion zone of the podocytes
to the basement membrane. The extrarenal localization of
gp330 is restricted to a limited number of organs, including
epididymis, pneumocytes type II, and the visceral yolk sac [65,
66]. In all cases, localization within organelles associated with
protein synthesis indicates that gp330 is synthesized by the
various cell types.
The pathogenic role of gp330 in the induction of Heymann
nephritis was established by two series of experiments. First,
using polyacrylamide gel electrophoresis in the presence of
sodium dodecyl sulfate (SDS-PAGE), it can be shown that
gp330 co-migrates with the brush-border protein identified by
glomerular eluates from rats with active Heymann nephritis [28,
29, 33] or by antibodies specific for RTEaS. This finding
provides a link with the classic studies performed by Edgington
et al, who isolated RTEa5 [201. Second, rats immunized with
gp330 (after the protein is affinity purified on sepharose-bound
lentil lectin or by using monoclonal antibodies) develop abun-
dant epimembranous deposits as well as heavy proteinuria [28,
29, 33]. Immunoperoxidase electron microscopy demonstrates
that the subepithelial electron-dense deposits contain both rat
IgG and gp330. This observation further documents that gp330
is the predominant—if not the sole—antigen involved in the
pathogenesis of Heymann nephritis. Passive Heymann nephri-
tis characterized by stable immune deposits could be induced
using polyclonal anti-gp330 antibodies [28, 29, 33, 67] and was
associated with significant proteinuria during the autologous
phase [681.
The events that take place after the initial binding of anti-
gp330 antibodies within a coated pit and the subsequent forma-
tion of electron-dense deposits have been intensely studied.
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The data available at present suggest that polyvalent antigen-
antibody interactions form highly cross-linked immune com-
plexes that are subsequently shed. The potential role in immu-
nopathology of such a process, recently reviewed by Andres et
al [69], was first advanced by Barba and colleagues [70], who
showed that angiotensin converting enzyme was removed from
the surface of lung endothelial cells after injection of polyclonal
antibodies raised against the enzyme. These authors postulated
that the large immune complexes formed were shed in the blood
stream and rapidly dissipated. Angiotensin converting enzyme
is also expressed on the oocyte membrane; Matsuo et al
visualized in "slow motion" a similar shedding process taking
place within the zona pellucida [71]. Three types of studies
provide new information that relates directly to the formation of
subepithelial electron-dense deposits in the glomerulus.
(1) The availability of polyclonal and monoclonal antibodies
to gp330, the latter specific for 6 different epitopes on the
antigen, prompted us to compare the ability of these antibodies
to induce subepithelial electron-dense deposits after injection in
vivo. We found that although immune deposits could be in-
duced by both monoclonal and polyclonal anti-gp330, electron-
dense deposits were only observed in rats given polyclonal
antibodies [67]. In the latter case, increased synthesis of gp330
could be demonstrated. Behar et al also found that monoclonal
antibodies to gp330 were unable to induce electron-dense
deposits [72].
(2) The cellular events taking place on the surface of the
glomerular epithelial cells have been studied in vitro [73—751.
Polyclonal bivalent antibodies induced both capping and release
of the immune complexes with a temporary disappearance of
the antigen from the cell surface. This energy-dependent pro-
cess requires a functional cytoskeleton as shown by experi-
ments carried out in the presence of cytochalasin B, colchicine,
or ionophore (A-23 187). Along the same lines, experiments by
Cybulsky and coworkers have shown that crosslinking of the
Heymann antigen by antibodies converts it from a detergent-
soluble, membrane-associated form to an insoluble cytoskele-
ton-bound form [76].
(3) Finally, Kerjaschki et al recently studied the early events
involved in the formation of immune deposits by polyclonal
antibodies to gp330 [77]. They showed that, as early as 15
minutes after injection, immune deposits are strongly bound to
the basement membrane by yet-undefined mechanisms. Fur-
thermore, immuno-ultrastructural analysis of serial glomerular
sections indicates that immune deposits remain in contact with
coated pits as long as 8 days after injection. The mechanisms
whereby immune complexes involving gp330 adhere to the
basement membrane are poorly understood. Mendrick and
colleagues suggested that gp330 might act as a receptor for
fibronectin [78]. In addition, the known reactivity of comple-
ment components with collagen might be of significance, be-
cause the antibodies involved are known to bind complement.
These experiments emphasize the importance of events that
occur after antibody binding; these events might help explain
the results of previous studies in which pretreatment of rats
with aminonucleoside of puromycin (PAN), known to be toxic
for glomerular epithelial cells, prevents the development of
passive Heymann nephritis [79]. This observation raises a
number of possibilities that might account for the lack of
formation of stable immune deposits, including lack of expres-
sion of the antigen or alterations in hemodynamics. These two
hypotheses probably can be ruled out because, as shown by
indirect immunofluorescence, gp330 apparently is normally
expressed (unpublished observations). In addition, administra-
tion of adriamycin [80], which produces nephrotic syndrome
with hemodynamic alterations identical to those observed dur-
ing the course of aminonucleoside nephrosis, does not alter the
development of passive Heymann nephritis. This observation
suggests to me that PAN might alter some of the processes that
occur after the initial antigen-antibody interaction; these pro-
cesses might include altered capping and release and/or abnor-
mal adherence of immune complexes to the glomerular base-
ment membrane, processes that might be related to altered
properties of either gp330 or basement membrane compo-
nent(s).
An enzymatic target involved in short-lived immune deposits:
gp9O. In the process of producing antibodies reactive with rat
brush border and glomeruli, we have selected two additional
monoclonal antibodies specific for a 90 kDa protein [32, 81]. On
immunofluorescence, the latter is intensely expressed not only
in the brush border, but also along the glomerular capillary wall
[62]. In contrast with gp330 [62], gp9O: (1) is not restricted to the
intermicrovillar region of the brush border but is detected over
the entire surface of microvilli; (2) is evenly distributed on the
membrane of glomerular epithelial cells; (3) is also expressed on
endothelial cells lining the glomerular capillary wall; and (4) has
a wide extrarenal distribution [31, 32, 65], including transport
epithelia such as gut, biliary pole of hepatocytes, capillary
endothelia, and the vast majority of normal lymphocytes [82].
This distribution suggested that the antigen was enzymatic in
nature and led us to identify gp9O as dipeptidyl peptidase IV
(DPP IV) [83].
The kinetics of the immune deposits that appear in the
glomerulus after intravenous injection of anti-gp9O monoclonal
antibody contrast sharply with those of deposits appearing after
injection of anti-gp330 monoclonal antibody [32, 81]. Glomeru-
lar binding is maximal 4 hours after injection but decreases very
rapidly from then on. During the same period, the anti-gp9O
monoclonal antibody can be found on the brush border and on
the basolateral aspect of proximal tubule cells. Similar kinetics
are observed after injection of polyclonal antibodies to gp9O and
suggest that the transient character of glomerular immune
deposits is not due to the antibody itself but is more likely
attributable to as-yet-undefined properties of the antigen.
The role played by gp9O in renal immunopathology in the rat
is poorly defined. Immunoglobulins eluted from glomeruli of
rats with active Heymann nephritis do not precipitate signifi-
cant amounts of gp9O [33]. This finding does not rule out the
possibility that the short-lived immune complexes involving
DPP IV formed on endothelial and/or epithelial cells are respon-
sible for an increase in glomerular permeability that may
enhance binding of antibodies to gp330. Along this line, a role
for endothelial immune complexes formed in situ was recently
suggested by Jeraj et al in passive Heymann nephritis [84] and
by Matsuo et al in a model of MGN induced in the rabbit by
polyclonal antibodies to angiotensin-converting enzyme [85].
In the mouse, the role of gp9O is easier to establish because
gp330 is not expressed in the glomerulus of this species.
Assmann and colleagues studied a model of MGN induced by
passive immunization with rabbit antibodies raised against
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Fig. 1. The immune deposits induced in vivo by nonocIonaI (A) or
polvclonal (B) antibodies specific frr gp330. The gp330 antigens are
depicted as solid circles along the surface of the foot process. A normal
podocyte is shown on the extreme left in both upper and lower panels.
Both types of antibodies bind to gp330 expressed on the membrane
areas of the podocyte membrane facing the glomerular basement
membrane. As can be seen, monoclonal antibodies are unable to induce
antigen redistribution and remain bound to the initial site of binding. By
contrast, polyclonal antibodies induce antigen redistribution, giving rise
to large, highly crosslinked immune complexes, which are subsequently
shed from the cell membrane and appear as large. epimembranous
deposits. Gp330. temporarily removed from the cell membrane, is
subsequently re-expressed as shown on the extreme right of the lower
panel.
mouse brush border digested by pronase (anti-TAPRON) [86,
87]. The kinetics of the heterologous phase bear close similarity
to those described in the rat given anti-gp9O antibodies, but the
amount of antibody remaining in the glomeruli is sufficient to
allow the development of an autologous phase [86]. Immuno-
precipitation of radiolabeled rat and mouse brush border dem-
onstrated that anti-TAPRON antisera contain antibodies to the
330 and 90 kDa brush-border proteins described: whereas the
anti-gp330 antibodies induce MGN after injection of anti-
TAPRON in the rat, only the anti-gp9O are nephritogcnic in the
mouse [86, 87].
Analysis of the specific pathogenetic role of the epithelial
expression of proteins such as gp9O in mice and rats is compli-
cated by their simultaneous endothelial expression in these two
species. This difficulty led us to study monoclonal antibodies
raised against rabbit brush border and specific for antigens
shared by brush-border and glomerular epithelia 1881. The first
one we identified has a molecular weight of 90 kDa and is DPP
IV. In contrast with the rat, the rabbit lacks expression of this
enzyme on glomerular endothelial cells. At the ultrastructural
level, the antigen is evenly distributed on the surface of
brush-border microvilli and glomerular epithelial cells [88]. The
kinetics of deposits induced by injection of monoclonal anti-
body to DPP IV in rabbits is reminiscent of that observed in the
rat; however, goat polyclonal antibodies raised against rabbit
DPP IV purified on a column of sepharose 4B linked to our
monoclonal antibody induced more persistent deposits and the
development of an autologous phase. This observation further
demonstrates that antigens expressed by glomerular epithelial
cells, but distinct from gp330, can be implicated in the forma-
tion of long-lasting immune deposits.
The second brush-border protein shared by glomerular epi-
thelial cells in the rabbit is enkephalinase (molecular weight, 85
kDa); it exhibits the same ultrastructural distribution as DPP IV
[88]. Glomerular deposits observed after injection in vivo of
monoclonal antibody to enkephalinase are particularly tran-
sient; their almost complete disappearance within 24 hours
coincides with the appearance of the antibody on the brush
border of some proximal convoluted tubules, as already noted
in the rat with anti-DPP IV.
Antigenic targets in humans. Identification of the antigens I
have described led us to search for their expression in humans
using the antibodies previously produced in our laboratory. We
have detected gp330 in humans only in the brush border, at least
at the immunofluorescence level. In contrast, cross-reactive
monoclonal antibodies and monospecific polyclonal antibodies
to DPP IV and enkephalinase bind not only human brush border
but also glomeruli [83]. The fluorescence pattern suggests that
the enzymes are expressed on the surface of the glomerular
epithelial cell.
Furthermore, using the strategy I previously described, we
produced a series of monoclonal antibodies to human brush
border [891. This approach provided us with two additional
monoclonal antibodies reactive with human glomeruli: one is
specific for human DPP IV, whereas the other identifies an 85
kDa protein diffusely expressed on the surface of brush-border
microvilli and glomerular epithelial cells. Sequential immuno-
precipitation indicates that the latter protein is identical to the
common acute lymphoblastic leukemia antigen previously de-
scribed by Platt et al on brush-border and glomerular epithelial
cells [90].
The list of potential antigenic targets obviously is not re-
stricted to proteins simultaneously expressed on brush-border
and glomerular epithelial cells. Antibodies that react with the
latter but not with the brush border have been produced in other
laboratories 191, 921. Except for one (which is specific for the
human equivalent of podocalyxin 193, 941), the corresponding
antigens have not been identified. Finally, recent data from
several groups suggest that monoclonal anti-DNA antibodies
may react with glomerular components [95—971. The central
question that remains is whether these antigens play a patho-
genetic role in human disease. Most eluates from kidneys of
patients with MGN do not react with normal kidney [17]. This
finding might reflect the fact that such eluates are prepared from
patients in the late stage of the nephropathy, when immune
deposits differ significantly from initial immune reactants. Re-
cently, Niles et al reported the binding of glomerular eluates to
a renal glycoprotein that was not fully characterized [98]; in
particular. its distribution within the renal parenchyma is un-
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human biopsies is promising. It should be complemented by a
careful analysis of the antigens contained in subepithelial im-
mune deposits using monoclonal antibodies of defined speci-
ficity.
In conclusion, the patient discussed here had typical mem-
branous glomerulonephritis induced by D-penicillamine. Re-
moval of the drug was associated with prompt regression of
clinical and pathologic symptoms. Data from experimental
studies suggest that several factors probably contributed to the
induction and evolution of the nephritis: (1) It seems likely that
the genetic background of the patient played a key role both in
his susceptibility to drug-induced nephritis and in the control
(autoregulation)of the nephritogenic antibody response;(2) The
properties of the antigenic target against which the antibodies
were directed also were likely to have been major determinants
of his particular manifestations.
Questions and answers
DR. JORDAN J. COHEN (Dean of Medicine, State University
ofNew York at Stony Brook, Stony Brook, New York): How is
gp330 related to clathrin? Is gp330 detected in immune deposits
in human idiopathic MGN?
DR. VERROuST: Clathrin and gp330 are two distinct proteins.
Although they are present in the same area of the membrane
(the intermicrovillar domain), gp330 is on the luminal aspect
and clathrin is on the cytoplasmic aspect [63, 64, 66].
No direct evidence currently links gp330 to the pathogenesis
of MON in humans. An antigen very similar to rat gp330 has
been demonstrated in the brush border of various species,
including humans [87, 99], but apparently it is not expressed by
glomerular epithelial cells, at least at the level of detection of
the methods used. The role of anti-gp330 in the induction of
immune deposits in human MON is thus largely, but not totally,
excluded. The question should remain open in view of the
observations by Matsuo et al in another system [85]. They
showed that injection of antibodies to angiotensin converting
enzyme could induce endothelial, and subsequently subepithe-
hal, deposits even though angiotensin converting enzyme is not
detectable on glomerular endothelial cells by conventional
immunohistologic techniques.
DR. L. A. VAN Es (Professor of Medicine, and Chief of
Nephrology, Leiden University, Leiden, The Netherlands):
What is the specificity of the nephritogenic antibodies in pa-
tients with membranous glomerulopathy?
DR. VERROUST: The specificity of the immunoglobulin depos-
ited in the glomeruli of patients with membranous glomerulo-
nephritis is at present unknown. Preliminary reports indicate
reactivity in some cases with a 95 kDa brush-border protein
[98], but further studies clearly are required.
DR. COHEN: Given our new understanding of the kinetics of
immune deposits in MGN, what insights have we gained
regarding more precise diagnosis and better treatment?
DR. VERROUST: I believe that the experimental data I pre-
sented emphasize the need to analyze glomerular epithelial cell
antigens in various forms of human renal disease in order to
determine the role of the biochemical and immunologic proper-
ties of the antigens involved. I would suggest that the different
types of MGN observed clinically might be related to immune
reactions specific for distinct antigens. I believe that advances
in this area will indeed be of direct clinical relevance for
followup and treatment.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): Are there any
known differences between the majority of patients who de-
velop membranous nephritis from D-penicillamine and those
few who develop mesangioproliferative glomerulonephritis?
DR. VERROUST: At present we do not have an indicator to
predict which patients will develop nephritis—and a fortiori its
type—after treatment with D-pencillamine.
DR. VAN Es: With regard to the specificity of the antibodies
involved in human membranous glomerulopathy, I would like
to report that Dr. van der Woude in our group has looked for
antibody reactivity in cultured epithelial cells from normal
glomeruli. This study was performed when he was in Dr.
Michael's laboratory in Minneapolis. He could not detect any
antibody reacting with the surface of these cells (unpublished
data).
DR. DONTSCHO KERJASCHKI (Professor of Pathology, Uni-
versity of Vienna, Institute of Pathological Anatomy, Vienna,
Austria): We recently obtained evidence that a membrane
protein indeed could be present in the immune deposits of
human membranous nephritis, as seen by immunoperoxidase
studies with a monoclonal antibody raised against a membrane
protein fraction from human glomeruhi.
I also would like to comment about the localization of
adhesion molecules on glomerular epithelial cells. One should
be aware that not every protein found on the interface between
glomerular cells and the matrix is an adhesion protein. We
recently localized molecules of the /31 integrin family (to which
the fibronectin receptor also belongs) in human glomeruli.
These molecules are associated with the cell membranes of
glomerular podocytes, of endothelial cells, and of mesangial
cells with high preference on the side of contact with the
glomerular basement membrane and the mesangial matrix,
respectively. We also discovered that this distribution remains
essentially unchanged in several glomerular diseases, including
membranous nephritis.
DR. LANDINO ALLEGRI (Researcher of Medicine, Institute of
Medical Clinic and Nephrology, University of Par,na, Parma,
Italy): You stressed that gp330 is the main antigen of Heymann
nephritis. Do you think that other antigens expressed by the
glomerular epithehial cell (such as podoendin or podocalyxin)
could have a pathogenetic role?
DR. VERROUST: Little information is available on the immu-
nopathologic role of podocalyxin [93] or podoendin [100]. The
data at hand suggest that the corresponding antibodies are not
highly (if at all) nephrotoxic. 1 would like to make a comment on
"alternative" or "additional" pathogenetic mechanisms in
Heymann nephritis. I believe that the role of humoral immune
reactions involving gp330 has been well established and can
account alone for most, if not all, the pathogenetic aspects of
Heymann nephritis. Thus, other possibilities that might be
considered should be compared critically with this known
system.
DR. KERJASCHKI: Is gp9O present on the base of the foot
processes?
DR. VERROUST: Yes, gp9O (that is, DPP IV) is present in this
area in the rat and rabbit. Neutral endopeptidase is also present
in this area in the rabbit.
1424 Nephrology Forum: Immune deposits in membranous nephropathy
DR. PEKKA HAYRY (Professor of Transplantation Surgery
and Immunology, University of Helsinki, Helsinki, Finland):
Do any of the experimental models of MGN evoke inflamma-
tion of the kidneys?
DR. VERROUST: No. The absence of inflammation is one of
the characteristics of human and of experimental MON. both of
which are histopathologically very similar.
DR. PHILIPPE DRUET (Professor of Medicine, Hopital Brous-
sais, INSERM U28, Paris, France): You mentioned that rats
injected with HgCI2 develop various antiglomerular-basement-
membrane antibodies, and then a membranous nephropathy.
That finding also was reported in the chronic graft-versus-host
reaction in the rat [101], in the neonatal tolerance model (M.
Goldman, personal communication), and in experimental try-
panosomiasis [102]. In addition, patients who develop protein-
uria following D-penicillamine treatment are reported to have
antibodies that recognize a laminin epitope [1031. Could you
comment on the role such antibodies could play in the appear-
ance of subepithelial deposits?
DR. VERROUST: It is indeed very interesting that anti-glomer-
ular-basement-membrane antibodies, particularly anti-laminin
antibodies, have been reported in a number of experimental
conditions in which their production (and pathogenetic role)
were not a priori expected. These antibodies might play an
ancillary role in diseases such as Heymann nephritis [104]. In
our experience with immunomorphologic studies, however, we
have never detected antibodies reactive with the glomerular
basement membrane.
Anti-laminin antibodies apparently play a more central role in
HgCI2-induced disease, including the formation of subepithelial
electron-dense deposits. They may operate via rearrangement
of immune complexes formed on the glomerular basement
membrane, bind basement membrane antigens expressed at
"unusual" sites on the epithelial cells, or react with "pre-
cursor" forms of laminin. In any case, this points once again to
the crucial role in the formation of stable subepithelial deposits
of an antigen that can associate closely with the basement
membrane.
DR. GIUSEPPE REMUZZI (Head, Laboratory of Kidney Dis-
eases, Mario Negri Institute for Pharmacological Research,
Bergamo, Italy): You mentioned that the transient or stable
nature of immune deposits is a function of the properties of the
antigen involved. Would you consider the possibility that
factors, such as reactive oxygen species, which appear to be
involved in the covalent binding of immune complexes to
glomerular basement membrane, also play a role in the persis-
tence of immune deposits in glomeruli?
DR. VERROUST: The binding of immune deposits via the
gp330 moiety to the glomerular basement membrane is very
strong [77] and suggests that it might be covalent. The biochem-
ical reaction(s) involved are unknown, and events such as those
you suggest indeed might be operative.
DR. EMILE DE HEER (Department of Pathology, University
of Leiden): Do you think that autoantibodies against gp330
require the activation of autologous complement to induce
epithelial cell damage? Or, as recently described by Mendrick
and Rennke, is perturbation of epitopes sufficient [105]? Pub-
lished studies have employed either heterologous antibodies or
an external complement source, either of which are likely to
bypass the complement-regulatory proteins involved in main-
taming the integrity of epithelial cells in an autologous system
[75, 106].
DR. VERROUST: Most of the experiments that have been
carried out so far have been performed in heterologous sys-
tems. They clearly demonstrate the requirement of the late
components of the complement cascade, the activation of
membrane attack complex for the induction of glomerular
epithelial cell damage and proteinuria. Experiments performed
during active Heymann nephritis obviously are not as detailed,
but deposition of membrane attack complex has been clearly
established [107—109] and related to the development of pro-
teinuria. Therefore I believe that it is legitimate to extend the
conclusions reached in passive Heymann nephritis. Perhaps Dr.
Kerjaschki could comment on some of his recent experiments
in this domain [110].
DR. KERJASCHKI: We recently localized the membrane attack
complex (in collaboration with Drs. Johnson and Couser) using
a monoclonal antibody specific for the new antigen expressed
by the assembled C5b-9 complex. We found that the membrane
attack complex is selectively removed from the immune depos-
its in passive Heymann nephritis by the podocyte cell mem-
branes and that it is concentrated in multivesicular bodies and
subsequently delivered by exocytosis of the contents of the
multivesicular bodies into the urinary space. The membrane
attack complex therefore can be recovered in the urine of rats
with Heymann nephritis; this indicates that membrane insertion
has taken place. Membrane insertion in the podocyte cell
membranes was further confirmed directly by freeze-fracture
electron microscopy in which the membrane attack complex
forms large (about 300 A diameter) intramembrane particles.
We have observed that these particles occur in the cell mem-
branes of flattened podocytes when proteinuria commences
(that is, 6 days after induction of passive Heymann nephritis)
but not at any previous time. This finding indicates that mem-
brane insertion of membrane attack complex coincides with the
onset of proteinurta, but the mechanisms linking these two
events remain unexplained.
DR. WOLFGANG THOENES (Director, Department of Pathol-
ogy, University of Mainz, Mainz, Federal Republic of Ger-
many): By contrast to so-called idiopathic membranous glomer-
ulopathy, the glomerulopathy induced by D-penicillamine is
particularly segmental. Do you have an explanation for this
phenomenon?
DR. VERROUST: At least two possibilities can be considered
that are not mutually exclusive: (I) MON induced by D-
penicillamine is diagnosed very early and regresses promptly in
most cases; thus, the disease might not have sufficient time to
evolve; (2) The target antigen might not be identical to that
involved in classic MGN.
DR. EBERHARD RITZ (Head, Division of Nephrology, Uni-
versity of Heidelberg, Heidelberg, Federal Republic of Ger-
many): Could you be more specific with respect to the actual
hapten involved in D-penicillamine-induced nephropathy? To
take this further, thiola (2 mercapto-proprionyl-glycine) is rec-
ommended as an alternative to D-penicillamine in the treatment
of cystinuria. Is there any evidence that it would be safe to
switch a patient from D-penicillamine to thiola after proteinuria
has developed?
DR. VERROUST: I am not aware that there is any evidence for
a "D-penicillamine-specific" immune response in the cases of
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MGN such as the one discussed today El 11]. It has been
suggested that patients who develop gold-induced MGN are
more susceptible to D-penicillamine-induced MGN [58]. I am
not aware of similar data concerning thiola and D-penicillamine.
DR. YVES PIRSON (Department of Nephrology, Cliniques
Universitaires St. Luc, Brussels, Belgium): You mentioned that
in cases of rapidly progressive glomerulonephritis (RPGN)
inducedby D-penicillamine, there is linear glomerular immuno-
globulin deposition. In fact, it was reported in only one case.
We recently reviewed the other cases of RPGN induced by
penicillamine; despite lung involvement in most of these pa-
tients, there was neither circulating anti-glomerular basement
membrane nor clear linear immunoglobulin deposition in the
kidney. Conversely, we recently observed 2 cases of necrotiz-
ing glomerulonephritis in patients taking penicillamine who had
circulating anticytoplasmic antibodies. Would you comment on
the significance of this finding?
DR. VERROUST: Very few patients who develop D-penicilla-
mine-induced renal disease have anything other than MGN [13,
112]. I do not have any definitive explanation to account for
those who manifest other patterns of renal damage, but the
general principles I have outlined might be relevant.
DR. PIRs0N: A significant number of patients who have
received transplants—2% to 5% in our experience—develop
de-novo membranous nephropathy after transplantation [113].
Do you have an idea of the target antigen in these patients?
DR. VERROUST: We do not have any data relevant to that
issue. Among the various possibilities, one might suggest an
immune response against yet-uncharacterized antigens; exper-
imental data by Dr. Thoenes [114] are compatible with this
hypothesis. Another possibility is an autoimmune response
against protein synthesized by glomerular epithelial cells in
response to some of the mediators involved in the rejection
process.
DR. CHARLES VAN YPERSELE (University of Louvain Medical
School, Hôpital St. Luc, Brussels): It hasbeen suggested by the
Guy's Hospital group that the best predictor of the renal
outcome of human membranous glomerulonephritis is the de-
gree of tubulointerstitial inflammation [115]. Does that tell us
something about the antigens involved in human disease?
DR. VERROUST: Tubulointerstitial damage has been reported
in Heymann nephritis by Mendrick et al [116]. In their experi-
mental conditions, tubular pathology clearly is antibody medi-
ated. This is not the case in human MGN, and I do not think
that this information can be used as evidence in favor of the
tubular expression of the pathogenetic antigen.
DR. JAN J. WEENING (Chief, Division of Immunopathology,
University of Groningen, Groningen, The Netherlands): Tubu-
lar brush-border antigens probably are not involved in human
membranous glomerulopathy; in biopsies of patients with overt
proteinuria associated with membranous GN, no tubular brush-
border staining is observed.
DR. E. H. 0. VAN LEER (Department of Pathology, Univer-
sity of Leiden): Recently Mendrick and Rennke described a
nephritogenic antigen apparently different from gp330 yet in-
ducing proteinuria [105]. Could you comment on this?
DR. VERROUST: The antigen you are alluding to is in fact very
similar to what we described as gp9O, particularly in terms of
tissue distribution. The endothelial pattern in particular does
suggest that it is DPP IV. We observed similar alterations of
glomerular epithelial cells upon intravenous injection (unpub-
lished observations), without proteinuria, as also reported by
Mendrick and Rennke in untreated rats [105].
DR. R. A. P. KOENE (Head, Division of Nephrology, Univer-
sity Hospital, Nijmegen, The Netherlands): You showed that
active Heymann nephritis cannot be induced in Lewis rats
pretreated with HgCI, and that these animals form almost no
anti-gp330 antibodies. One of the mechanisms of this protection
might be that HgCl2 binds to the immunogenic site of the gp330
antigen, thus preventing the immune response. If this were the
case, it also would bind to gp330 in the kidney. One would
expect that this binding also could modify the course of
Heymann nephritis induced by the administration of anti-gp330
antibodies, because the injected antibody cannot bind to its
target in the kidney. Have such studies in passive Heymann
nephritis been carried out?
DR. VERROUST: We have verified that in-vitro and in-vivo
binding of monoclonal or polyclonal anti-gp330 to renal tissue
from HgCl2-treated Lewis rats is unaltered [491.
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